Accelerating Drug Development with AI and Blockchain

ICON’s 2023 Biotech Survey explores how biotech companies are adapting to significant declines in funding availability.

Key data shows 60% plan to increase R&D spend despite constraints, 51% have 4+ active trials, and 93% are confident in hitting next milestones. However, companies face hurdles like clinical trial complexity, talent gaps, and uncertain macroeconomic factors. Biotech innovation persists despite funding woes. Don’t let budget cuts derail your clinical programs. Luminari CRO leverages AI and blockchain to optimize trials and accelerate results. We welcome the opportunity to have an informational discussion about whether our optimized platforms could potentially enhance your development initiatives. Luminari Opinion: While biotech’s tighten budgets, patient recruitment and trial efficiency matter more than ever. Our AI-enabled platform identifies eligible candidates faster while blockchain enhances data integrity. With median trial costs topping $40 million (Tufts CSDD), maximizing patient matches and optimizing data quality is imperative. We help clients stretch R&D dollars through technology integration. Our scientific team would be glad to analyze innovative integration opportunities that may align with advancing your pipeline’s specific needs. [Source: ICON, 2023 Biotech Sector Survey: Navigating Biotech’s Challenges and Embracing a Promising Tomorrow]